These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37162497)

  • 21. Intermittent androgen deprivation therapy in advanced prostate cancer.
    Alva A; Hussain M
    Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The truth is out there: an overall perspective on androgen deprivation.
    Hellerstedt BA; Pienta KJ
    Urol Oncol; 2003; 21(4):272-81. PubMed ID: 12954498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists.
    Fragkoulis C; Glykas I; Dellis A; Mitsogiannis I; Papatsoris A
    Arab J Urol; 2021; 19(4):460-463. PubMed ID: 34881062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
    Sari Motlagh R; Abufaraj M; Mori K; Aydh A; Rajwa P; Katayama S; Grossmann NC; Laukhtina E; Mostafai H; Pradere B; Quhal F; Karakiewicz PI; Enikeev DV; Shariat SF
    Eur Urol Oncol; 2022 Apr; 5(2):138-145. PubMed ID: 34301529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer.
    Shore ND; Sutton J
    Future Oncol; 2022 Jul; 18(21):2575-2584. PubMed ID: 35587650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician.
    Siebert AL; Lapping-Carr L; Morgans AK
    Eur Urol Focus; 2020 Nov; 6(6):1170-1179. PubMed ID: 32690473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal.
    Gourdin T
    Curr Opin Oncol; 2021 May; 33(3):252-256. PubMed ID: 33818543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
    Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
    Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management.
    Mohler JL
    J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):663-5. PubMed ID: 27226508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relugolix (Orgovyx) for advanced prostate cancer.
    Med Lett Drugs Ther; 2023 Jul; 65(1681):e121-e122. PubMed ID: 37460145
    [No Abstract]   [Full Text] [Related]  

  • 32. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
    Yang DD; Mahal BA; Muralidhar V; Martin NE; Orio PF; Mouw KW; King MT; Choueiri TK; Trinh QD; Hoffman KE; Spratt DE; Feng FY; Nguyen PL
    Eur Urol; 2019 Jan; 75(1):35-41. PubMed ID: 30554605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
    Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
    Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-dependent overall survival benefit of androgen deprivation therapy for metastatic prostate cancer.
    Keating MJ; Giscombe L; Tannous T; Reddy N; Mukkamalla SKR; DeSouza A; Rathore R
    J Oncol Pharm Pract; 2019 Dec; 25(8):1927-1932. PubMed ID: 30880568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-prostatectomy adjuvant androgen deprivation therapy- Current opinions and practices of Canadian urologists.
    Levitt M; Nayak AL; Fergusson DA; Lavallee LT; Morash C; Cagiannos I; Flaman AS; Breau RH
    Urol Oncol; 2022 Feb; 40(2):57.e9-57.e14. PubMed ID: 34303596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to guidelines for androgen deprivation therapy after radical prostatectomy: Swedish population-based study.
    Lycken M; Drevin L; Garmo H; Larsson A; Andrén O; Holmberg L; Bill-Axelson A
    Scand J Urol; 2020 Jun; 54(3):208-214. PubMed ID: 32338176
    [No Abstract]   [Full Text] [Related]  

  • 38. Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?
    Lycette JL; Bland LB; Garzotto M; Beer TM
    Clin Genitourin Cancer; 2006 Dec; 5(3):198-205. PubMed ID: 17239273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers.
    Fang D; Zhou L
    Asia Pac J Clin Oncol; 2019 Jun; 15(3):108-120. PubMed ID: 30729683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer.
    Foulkes SJ; Daly RM; Fraser SF
    Endocr Relat Cancer; 2017 Mar; 24(3):R35-R48. PubMed ID: 28062546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.